TMPS

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of TMPS

Quick Facts

Property	Description
Active Ingredients	Sulfadoxine and Trimethoprim
Form	Tablets, Oral liquid, Intravenous solution
Pharmacological Class	Potentiated Antimicrobial, Antibiotic
Common Use	Combating Bacterial and Protozoal Infections
Origin	Synthetic

What is TMPS and What Type of Medicine Is It?

The drug known as TMPS is a synthetic, potentiated antimicrobial agent, specifically defined as a fixed-dose combination (FDC) medicine. It belongs to the high-level antibiotic class and is precisely categorized as an antifolate drug because its therapeutic activity targets the critical metabolic steps required for microbial survival. The core principle of its design is to offer a robust and reliable defense against susceptible infectious agents.

Composition: Sulfadoxine, Trimethoprim, and the Potentiated Effect

The active composition of TMPS comprises two distinct synthetic molecules: Sulfadoxine, a sulfonamide antibiotic, and Trimethoprim, a diaminopyrimidine antimicrobial. This specific pairing is the basis for several global formulations, often utilizing the long-acting nature of Sulfadoxine. This fixed pairing ensures that both substances are delivered simultaneously in the necessary ratio to activate their complementary functions. TMPS is prepared for administration via the oral route as tablets or an oral liquid, and for serious infections, as a sterile solution for intravenous infusion.

How Does the Combination Provide a General Benefit?

The combined action of the two agents results in the unique principle known as sequential blockade. This synergistic mechanism stops microorganisms from creating the vital nutrient folic acid they require for building their genetic material and multiplying. This type of combination strategy is clinically recognized for significantly enhancing efficacy against a range of microbes. This powerful dual attack results in a bactericidal effect, meaning the combination actively kills the susceptible microbes rather than merely inhibiting their growth, offering a significant general therapeutic benefit.

Regulatory References

NIH - Trimethoprim Sulfamethoxazole Information

What side effects are possible with TMPS?

Possible Side Effects and Safety Information

The safety profile of TMPS (Sulfadoxine/Trimethoprim) is officially documented by government regulatory bodies, classifying potential effects by system and frequency. Adverse reactions are grouped across multiple System-Organ-Classes (SOC), notably the Gastrointestinal System, the Skin and Subcutaneous Tissue, and the Blood and Lymphatic System.

According to regulatory data, the most common adverse effects are typically gastrointestinal disturbances (such as nausea, vomiting, and loss of appetite) and certain allergic skin reactions (including rash and hives).

Serious Adverse Reactions and Safety Constraints

The medicine is associated with rare, potentially fatal serious adverse reactions which include severe blood disorders (agranulocytosis, aplastic anemia), severe cutaneous reactions (like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)), and fulminant hepatic necrosis.

Time-related patterns are noted: the risk for SJS or TEN is highest within the first weeks of treatment. Conversely, severe diarrhea (C. difficile-associated) may appear even after treatment completion.

Population-specific safety restrictions are explicit in the labeling. The product is contraindicated in infants younger than two months and in patients with marked hepatic damage or severe renal insufficiency when monitoring is unavailable. Older adults may be at increased risk for certain severe effects, including hyperkalemia and hematological changes. Use during pregnancy and lactation is generally restricted due to potential risks to the fetus or infant.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile for this sulfonamide/trimethoprim combination by detailing specific acute signs and the severe risks associated with prolonged over-exposure.

Documented Overdose Manifestations

Acute overdose is formally documented to present with several systemic and neurological changes. Manifestations may include vomiting, fever, confusion, and a progression toward loss of consciousness. Other documented signs include loss of appetite (anorexia), the potential for blood in the urine (hematuria), and yellowing of the skin or eyes (jaundice).

Chronic overdosage is officially associated with an increased risk of severe hematological outcomes, such as bone marrow depression and the development of megaloblastic anemia due to prolonged antifolate effects. Population-specific notes indicate that elderly patients with pre-existing renal or hepatic impairment are at an increased risk of serious effects.

Regulator-Mandated Emergency Actions

Regulatory authorities mandate that patients seek immediate medical attention for the onset of any acute overdose symptoms. Urgent help is required for any signs concerning the level of consciousness or systemic distress. Treatment is officially defined as symptomatic and supportive. For acute oral poisoning, procedures described in labeling include gastric lavage and the administration of activated charcoal. To address the risk of chronic hematological toxicity, the administration of Leucovorin (calcium folinate) is described as a specific management measure.

Therapeutic Uses of TMPS

The primary role of this potentiated antimicrobial agent is to manage infections caused by susceptible bacteria and protozoa that cause acute and disruptive symptomatic episodes in various body systems. This agent is commonly used to help with infections across several therapeutic domains, providing support that helps ease the overall symptom burden.

This medication is relevant for easing symptoms related to inflammatory or irritative states in the urinary tract, such as painful, frequent urination, and for managing symptoms that create noticeable physiological strain in the gastrointestinal and respiratory tracts, like acute diarrhea and cramping, or flare-ups of chronic bronchitis. A relevant application of this agent is its use in therapy for serious protozoal infections (e.g., Pneumocystis pneumonia) in high-risk, immunosuppressed patient groups. It is commonly used to prevent these infections from developing or recurring, which is relevant when supportive symptom management is appropriate.

Quick Fact: Relief for Acute Infection Symptoms
Symptom Domains Addressed	Urogenital discomfort, severe infectious diarrhea, respiratory distress, and fever associated with infection.
Typical Scenario	Treating sudden-onset (acute) bacterial or protozoal infections, or long-term prophylaxis in high-risk patients.
General Benefit	Supports the easing of the overall symptom burden and assists with maintaining functional stability during symptomatic periods.

Regulatory References

NIH StatPearls overview on Co-trimoxazole

Eligibility and Restrictions for Use

The eligibility to use the fixed-dose combination TMPS (Sulfamethoxazole and Trimethoprim) is strictly defined by regulatory documents based on a patient’s medical history, age, and organ function.

Absolute Contraindications

TMPS is contraindicated (must not be used) in patients with known hypersensitivity to trimethoprim or sulfonamides. Use is strictly prohibited for individuals with marked hepatic damage, severe unmonitored renal insufficiency, or megaloblastic anemia due to folate deficiency. The medicine is also contraindicated for pregnant or nursing mothers and for infants less than two months of age.

Age and Conditional Use

Use is established for pediatric patients two months of age and older, adolescents, and adults. Use in older adults requires caution and close monitoring due to increased risk factors. Patients with impaired renal function (Creatinine Clearance 15 to 30 mL/min) or impaired hepatic function that is not classified as marked damage require conditional use and close observation. Caution is also needed for patients with G6PD deficiency or those predisposed to folate deficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail several critical interactions for Trimethoprim-Sulfamethoxazole (TMPS), primarily related to altered drug metabolism and synergistic effects.

Documented Interaction Profile

Category of Interacting Medicine	Specific Medicines Listed	Required Regulatory Action/Constraint
Antiarrhythmics	Dofetilide	Contraindicated due to risk of increased Dofetilide concentration and ventricular arrhythmias.
Oral Anticoagulants	Warfarin	Requires frequent monitoring of International Normalized Ratio (INR) due to increased bleeding risk.
Antifolate Drugs	Methotrexate, Pyrimethamine	Requires close monitoring of hematological parameters due to enhanced toxicity (e.g., bone marrow suppression).
Diuretics/ACE Inhibitors/ARBs	Thiazides, Potassium-sparing diuretics, Lisinopril	Requires frequent monitoring of serum potassium and renal function due to risk of severe hyperkalemia.
Anticonvulsants	Phenytoin	Requires monitoring of Phenytoin plasma levels due to inhibited metabolism leading to toxicity.
Hypoglycemic Agents	Repaglinide, Acetohexamide	Requires close monitoring for signs of hypoglycemia due to enhanced effects.

Official Regulatory Statement

The interaction profile is structured around the inhibition of renal tubular transporters by trimethoprim and the inhibition of specific cytochrome P450 enzymes (CYP2C9) by sulfamethoxazole, in addition to pharmacodynamic effects. Government labeling explicitly identifies the need for laboratory monitoring (e.g., INR, potassium levels, blood counts) when combining TMPS with these medicines and establishes an absolute prohibition for use with Dofetilide. These constraints define the official requirements for use based purely on the documented interaction risks.

Mechanism of Action

How TMPS Works: The Sequential Blockade

The medicine exerts a selective toxicity by implementing a Sequential Blockade against the microbial Folate Biosynthesis Pathway—a process absent in human cells. Sulfadoxine acts as a competitive inhibitor of Dihydropteroate Synthase (DHPS), while Trimethoprim inhibits Dihydrofolate Reductase (DHFR), thus creating a dual barrier to the production of the active co-factor, Tetrahydrofolate.

Synergistic Cascade and Cell Mortality

This dual-step inhibition results in a synergistic cascade where the inhibition of the first enzyme potentiates the effect of the second, leading to a profound depletion of the required Tetrahydrofolate ( THF) pool. The resulting failure to synthesize DNA and proteins arrests microbial replication and initiates a definitive bactericidal effect, leading to the irreversible death of the susceptible microorganism.

Mechanism Constraints: Evasion and Resistance

The effectiveness of this mechanism is constrained by genetic changes in target organisms, such as structural mutations in the target enzymes. These mutations reduce the drug's binding affinity, which functionally limits the sequential blockade and defines the boundaries of the drug’s physiological applicability.

Dosage and Administration Information

How to Use TMPS: Administration Guidelines

TMPS is an antimicrobial medicine that is administered via two primary routes, based on the severity of the condition being managed. It is available for oral use as tablets and a liquid suspension, and for systemic use in severe infections, as a sterile solution for intravenous (IV) infusion.

Dosing and Frequency Patterns

The standard adult therapeutic dose is typically 160 mg of the Trimethoprim component in combination with 800 mg of the Sulfonamide component, taken twice daily (every 12 hours). For severe or life-threatening infections, such as certain protozoal diseases, the dose escalates to a weight-based regimen (up to 20 mg/ kg/ day of the Trimethoprim component) which may be administered three or four times daily.

Treatment courses are precisely time-bound: common acute infections generally require an intermediate duration of 10 to 14 days, while some specific acute enteric infections may require as few as 5 days. The most extended duration, for severe protozoal infections, is typically 14 to 21 days.

Administration Requirements and Adjustments

For oral administration, guidelines recommend taking the medicine with a full glass of water to assist with proper absorption. The liquid suspension must be shaken well prior to use. The IV concentrate is not administered directly; it must be diluted in a suitable fluid, such as Dextrose 5% in Water, before being delivered via a slow infusion over 60 to 90 minutes.

Dosing requires modification for specific populations: use is not authorized for infants under two months of age. Furthermore, patients with documented renal impairment (creatinine clearance between 15 and 30 mL/ min) must receive a reduced dosage.

Recent Clinical Evidence

Research Evidence / Overview of Studies for TMPS

This section provides an overview of the types of research studies conducted to evaluate the combination of sulfadoxine and trimethoprim, focusing on the evidence cited in authoritative governmental and peer-reviewed scientific sources. The findings describe patterns observed in patient groups but do not determine individual outcomes.

Evidence for Use in Protozoal and Acute Infections

The research base for serious protozoal infections, such as Pneumocystis jirovecii pneumonia (PCP), utilized long-term observational studies and randomized controlled trials (RCTs). These studies were applied in research contexts involving immunosuppressed patient groups, including HIV-positive individuals and transplant recipients. Studies monitored the incidence of PCP episodes and clinical responses, including morbidity and mortality rates. This research is frequently referenced for both the acute treatment and prevention of PCP in numerous scientific guidelines.

Evidence for Use in Urogenital and Respiratory Tract Infections

Research examined the use of the drug combination for acute infections. For Urinary Tract Infections (UTIs), short-term RCTs conducted in non-pregnant adults and pediatric patients measured clinical resolution and bacteriological clearance. Findings reported high rates of clearance for specific susceptible pathogens, and the evidence is referenced in guideline documents. For Acute Exacerbations of Chronic Bronchitis (AECB), studies monitored outcomes in adults, reporting measurements related to changes in respiratory symptoms in bacterial exacerbations.

Long-Term Outcomes and Research Uncertainty

Research has explored long-term outcomes, particularly in prevention settings where follow-up durations were extended over months to years. For acute infections, follow-up was typically limited to days or weeks. The combination was studied across various populations, including pediatric and immunosuppressed groups, though data for certain subgroups and older adults remain less extensive.

Microbial resistance is a recognized scientific area of focus within the evidence landscape. Scientific literature notes that this factor affects the drug combination’s current utility, especially compared to the time when the original pivotal trials were conducted. Long-term outcomes for non-prophylaxis use are not yet fully established.

Frequently Asked Questions (FAQ)

Common questions about TMPS (FAQ)

Q: Does TMPS make you feel sleepy?

Official regulatory documents list certain central nervous system (CNS) effects that may be experienced. These include feelings of dizziness or vertigo. Additionally, official information mentions a neurological effect called ataxia, which is described as a lack of muscle coordination or balance. If these effects are experienced, it is recommended to discuss them with a healthcare professional.

Q: Can TMPS cause dry mouth?

Dry mouth itself is not commonly cited as a frequent side effect in primary regulatory listings. However, official safety information notes that dry mouth, along with increased thirst, can be a sign of hyperkalemia (high blood potassium). This is a change that may require monitoring. Such changes are important to mention to a healthcare professional.

Q: Is it important to avoid alcohol while taking TMPS?

According to official product information, it is generally recommended to avoid consuming alcohol while taking this medicine. The combination of TMPS and alcohol may cause an adverse reaction. Such a reaction could potentially result in symptoms such as flushing, nausea, vomiting, or headache.

Q: Can I take an OTC pain reliever (like ibuprofen or acetaminophen) with TMPS?

Regulatory documents detail that caution is needed when combining TMPS with other medications, even over-the-counter ones. TMPS may interact with drugs that affect potassium levels or certain blood thinners (anticoagulants). For this reason, official sources indicate that use of unlisted over-the-counter products should be approached with caution.

Q: Does TMPS interact with vitamins or herbal supplements?

The official warning for TMPS advises that patients should share a complete list of all other medications, including vitamins, herbal remedies, and supplements. This is due to the potential for interactions between TMPS and certain substances that affect how the body processes blood or manages kidney function, which could increase risks.

Q: Do I have to take TMPS with food?

Official guidance emphasizes that the medicine should be taken with a full glass of fluid to assist with proper administration. While taking it specifically with food is not mandatory, doing so may help to reduce the chance of experiencing stomach upset or other common gastrointestinal disturbances.

Q: Is it common to feel fatigued or unusually tired on TMPS?

Yes, regulatory listings acknowledge that both fatigue and a general feeling of tiredness or weakness are among the potential adverse effects associated with this medication. These effects are reported in the official safety profile for TMPS.

Q: If I miss a dose, what should I do?

Official patient instructions indicate that if a dose is missed, taking it as soon as it is remembered is an option. However, if it is almost time for your next scheduled dose, you should skip the missed dose and return to your regular dosing schedule. Official instructions specify that double doses should not be taken to compensate for a missed dose.

Q: Can TMPS cause me to be allergic to other drugs?

TMPS is specifically categorized as a sulfonamide antibiotic. Official contraindications state that the medicine should not be used by anyone with a known hypersensitivity or allergy to trimethoprim or sulfonamides themselves. It is important that any known drug allergies are shared with the prescribing physician.

How should TMPS be stored and disposed of?

How to Store and Dispose of Trimethoprim-Sulfamethoxazole (TMP/SMX)

Official labeling defines strict conditions for storing and handling TMP/SMX in all forms.

Storage Requirements

Dosage Form	Required Storage Condition
Tablets / Oral Suspension	Controlled Room Temperature (20 C to 25 C / 68 F to 77 F); Oral Suspension must be protected from light; Tablets stored in a tight, light-resistant container.
Injection Solution	Controlled Room Temperature; Do not refrigerate concentrate or diluted solution.

Stability and Handling

The diluted intravenous solution has a limited shelf-life (e.g., 4 to 6 hours) and must be discarded if cloudiness or crystallization is observed. All medicine must be kept out of the sight and reach of children.